Kazia Therapeutics Limited Adr (KZIA)

Apr 13, 2026

Kazia Therapeutics (NASDAQ: KZIA) licenses SETDB1 platform, pays $1.39M upfront - Stock Titan

Apr 13, 2026

Apr 13, 2026

Kazia (NASDAQ: KZIA) licenses SETDB1 platform, plans $6M dual-program push - Stock Titan

Apr 13, 2026

Apr 13, 2026

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - Bitget

Apr 13, 2026

Apr 13, 2026

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - Benzinga

Apr 13, 2026

Apr 09, 2026

Kazia Therapeutics (KZIA) CEO updates ADS option exercise price details - Stock Titan

Apr 09, 2026

Apr 02, 2026

KZIA Stock Price, Quote & Chart | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill

Apr 02, 2026

Apr 01, 2026

Kazia Therapeutics (KZIA) executive discloses multiple stock option positions - Stock Titan

Apr 01, 2026

Mar 31, 2026

95,110 ADS supplement and director exit — Kazia (NASDAQ: KZIA) - Stock Titan

Mar 31, 2026

Mar 31, 2026

Kazia Therapeutics (NASDAQ: KZIA) holder reports 1.59M ADS; 13.90% stake - Stock Titan

Mar 31, 2026

Mar 30, 2026

Alumni Capital exits KZIA holdings (KZIA) — 0 ADS as of Jan 30, 2026 - Stock Titan

Mar 30, 2026

Mar 19, 2026

Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADSs, reports $69.46M cash - Stock Titan

Mar 19, 2026

Mar 19, 2026

Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADSs; posts half‑year update - Stock Titan

Mar 19, 2026

Mar 19, 2026

Kazia Therapeutics (NASDAQ: KZIA) files prospectus supplement for 232,956 ADSs - Stock Titan

Mar 19, 2026

Mar 19, 2026

Kazia Therapeutics (KZIA) raises major cash despite $12.6m loss - Stock Titan

Mar 19, 2026

Mar 18, 2026

Kazia Therapeutics (NASDAQ: KZIA) director Coffey details ADS options and share stakes - Stock Titan

Mar 18, 2026

Mar 18, 2026

Kazia Therapeutics (KZIA) CEO discloses multi-million share option stakes on Form 3 - Stock Titan

Mar 18, 2026

Mar 18, 2026

Kazia Therapeutics (KZIA) VP discloses initial ADS option grants - Stock Titan

Mar 18, 2026

Mar 17, 2026

Kazia Therapeutics (NASDAQ: KZIA) files $200M shelf; $100M ATM with Leerink - Stock Titan

Mar 17, 2026

Mar 07, 2026

Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail

Mar 07, 2026

Feb 20, 2026

Jorey Chernett holds 12.46% of Kazia Therapeutics (KZIA) ADS - Stock Titan

Feb 20, 2026

Feb 17, 2026

Ikarian Capital discloses 5.1% Kazia Therapeutics (KZIA) ADS position - Stock Titan

Feb 17, 2026

Feb 12, 2026

Dauntless Investment trims Kazia Therapeutics (KZIA) position to negligible 0.0% - Stock Titan

Feb 12, 2026

Jan 30, 2026

Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data By Investing.com - Investing.com India

Jan 30, 2026

Jan 30, 2026

Kazia Therapeutics stock rises on promising nuclear PD-L1 degrader data - Investing.com UK

Jan 30, 2026

Jan 30, 2026

Experimental cancer drug targets hidden resistance driving metastasis - Stock Titan

Jan 30, 2026

Jan 27, 2026

Kazia Therapeutics (NASDAQ: KZIA) posts early TNBC trial gains in paxalisib study - Stock Titan

Jan 27, 2026

Jan 27, 2026

Early paxalisib TNBC responses highlighted by Kazia Therapeutics (NASDAQ: KZIA) - Stock Titan

Jan 27, 2026

Jan 27, 2026

Early paxalisib TNBC data: Kazia Therapeutics (NASDAQ: KZIA) sees partial and complete responses - Stock Titan

Jan 27, 2026

Jan 01, 2026

United States shares mixed at close of trade; Dow Jones Industrial Average up 0.66% _newTouch_By Investing.com - Investing.com India

Jan 01, 2026

Dec 31, 2025

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.66% - Investing.com

Dec 31, 2025

Dec 23, 2025

Kazia Therapeutics (KZIA) resale filing details $46.5M cash boost and runway to 2028 - Stock Titan

Dec 23, 2025

Dec 20, 2025

Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance - The Globe and Mail

Dec 20, 2025

Dec 08, 2025

Kazia Therapeutics secures $46.5 million through private placement to address Nasdaq compliance - MSN

Dec 08, 2025

Dec 06, 2025

Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance - The Globe and Mail

Dec 06, 2025

Dec 03, 2025

You might want to take a look at Kazia Therapeutics Limited ADR (KZIA) now - setenews.com

Dec 03, 2025

Dec 02, 2025

Kazia Therapeutics (NASDAQ: KZIA) expects $46.5M net from PIPE to extend cash runway - Stock Titan

Dec 02, 2025

Nov 26, 2025

Check out these key findings about Hub Cyber Security Ltd (HUBC) - setenews.com

Nov 26, 2025

Nov 26, 2025

What is Kazia Therapeutics Limited ADR (KZIA) Stock Return on Shareholders’ Capital? - Setenews

Nov 26, 2025

Nov 25, 2025

Kazia Therapeutics Limited (KZIA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Nov 25, 2025

Nov 22, 2025

Kazia Therapeutics reports immune complete response in TNBC - MSN

Nov 22, 2025

Nov 19, 2025

KZIA Shares Surge: Can This Momentum Last? - StocksToTrade

Nov 19, 2025

Nov 19, 2025

Kazia Therapeutics (KZIA) Stock Soars on Breakthrough Results in Breast Cancer Treatment - parameter.io

Nov 19, 2025

Nov 18, 2025

Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing By Investing.com - Investing.com India

Nov 18, 2025

Nov 18, 2025

Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing - Investing.com

Nov 18, 2025

Nov 18, 2025

Kazia Therapeutics Achieves Initial iCR… - digitalmore.co

Nov 18, 2025

Nov 18, 2025

Kazia reports immune-complete response in metastatic breast cancer By Investing.com - Investing.com South Africa

Nov 18, 2025

Nov 18, 2025

Kazia reports immune-complete response in metastatic breast cancer - Investing.com

Nov 18, 2025

Nov 18, 2025

Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - The Manila Times

Nov 18, 2025

Nov 18, 2025

Kazia stock soars after patient shows complete response in TNBC trial - Investing.com Nigeria

Nov 18, 2025